Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
Immunome (Nasdaq: IMNM), a biotechnology company specializing in targeted cancer therapies, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. Clay Siegall, PhD, President and CEO, will engage in a fireside chat on Wednesday, November 13th at 10:30am Eastern Time. The presentation will be accessible via live audio webcast through the company's website's Investor Relations section, with a replay available for approximately 30 days post-event.
Immunome (Nasdaq: IMNM), una società biotecnologica specializzata in terapie oncologiche mirate, ha annunciato la sua partecipazione alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim. Clay Siegall, PhD, Presidente e CEO, parteciperà a una conversazione informale mercoledì 13 novembre alle 10:30 ora orientale. La presentazione sarà disponibile tramite un webcast audio dal vivo nella sezione Relazioni con gli Investitori del sito web dell'azienda, con una registrazione disponibile per circa 30 giorni dopo l'evento.
Immunome (Nasdaq: IMNM), una empresa biotecnológica especializada en terapias contra el cáncer dirigidas, ha anunciado su participación en la Conferencia Inaugural de Innovación en Salud de Guggenheim. Clay Siegall, PhD, Presidente y CEO, participará en una charla informal el miércoles 13 de noviembre a las 10:30 a.m. hora del Este. La presentación estará disponible a través de una transmisión en vivo por audio a través de la sección de Relaciones con Inversores en el sitio web de la empresa, con una repetición disponible durante aproximadamente 30 días después del evento.
Immunome (Nasdaq: IMNM), 표적 암 치료를 전문으로 하는 생명공학 회사가 구겐하임의 첫 번째 의료 혁신 컨퍼런스에 참여한다고 발표했습니다. Clay Siegall, PhD, 사장 겸 CEO는 11월 13일 수요일 오전 10시 30분 동부 표준시에 대담에 참여할 예정입니다. 프레젠테이션은 회사 웹사이트의 투자자 관계 섹션을 통해 실시간 오디오 웹캐스트로 제공되며, 이벤트 후 약 30일 동안 재생할 수 있습니다.
Immunome (Nasdaq: IMNM), une entreprise biopharmaceutique spécialisée dans les thérapies ciblées contre le cancer, a annoncé sa participation à la première conférence sur l'innovation en santé de Guggenheim. Clay Siegall, PhD, président et CEO, participera à une discussion informelle le mercredi 13 novembre à 10h30, heure de l'Est. La présentation sera accessible via un webinaire audio en direct dans la section Relations Investisseurs du site Web de l'entreprise, avec une rediffusion disponible pendant environ 30 jours après l'événement.
Immunome (Nasdaq: IMNM), ein biotechnologisches Unternehmen, das sich auf zielgerichtete Krebstherapien spezialisiert hat, hat seine Teilnahme an der ersten Gesundheitsinnovationskonferenz von Guggenheim angekündigt. Clay Siegall, PhD, Präsident und CEO, wird am Mittwoch, den 13. November um 10:30 Uhr Eastern Time an einem Fireside-Chat teilnehmen. Die Präsentation wird über einen Live-Audio-Webcast im Bereich Investor Relations der Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die etwa 30 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted in the first quarter of 2025. For more information, visit www.immunome.com.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expected timing for submission of INDs for its programs and other statements regarding management’s intentions, plans, beliefs, estimates or forecasts for the future based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including risks and uncertainties indicated from time to time described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 12, 2024 and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105740255/en/
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
Source: Immunome, Inc.
FAQ
When is Immunome (IMNM) presenting at Guggenheim's Healthcare Innovation Conference?
How can investors access Immunome's (IMNM) presentation at the Guggenheim conference?
How long will Immunome's (IMNM) presentation replay be available?
What type of presentation will Immunome (IMNM) give at the Guggenheim conference?
